| Literature DB >> 31338477 |
Gina M McCaskill1,2, Olivio J Clay1, Robert W Motl3,4, Karlene K Ball1.
Abstract
Entities:
Year: 2019 PMID: 31338477 PMCID: PMC6626999 DOI: 10.1016/j.conctc.2019.100395
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
Fig. 1Flowchart of procedures.
Feasibility Metrics for OVERTURE II
| Metric | Reason | Method | Importance |
|---|---|---|---|
| Recruitment | Mass mailing using Center’s research database | Can be used to determine the most effective approach to recruitment for Phase II and III studies. | |
| Retention | Ratios and proportions to determine the percentage of participants retained for the study. | ||
| Attrition | Ratios and proportions to determine the percentage of participants dropped from study and reasons for withdrawal. | ||
| Adherence | Assess adherence based on participants’ adherence logs. | ||
| Participant communication | Evaluate the cost of establishing and maintaining communication with participants through mail, telephone, and in-person | Determine the most effective method for communicating with participants, which will be adopted for future studies. | |
| Incentives | Evaluate the cost of the all incentives | Can be used to estimate the cost of large Phase II and Phase III studies. | |
| Program costs | Evaluate the overall program’s financial costs from pre-study to post-study | ||
| Obtain IRB approval | Assess the length of time and personnel efforts in the preparation and approval of the IRB | Can provide insight on the time and effort required to start the next phase of the study | |
| Clinical Trial registration | Registration of the trial in the Federal government’s database for clinical trials. Determine the length of time and personnel effort | ||
| Training of staff | Determine the amount of time required to train all staff | Can provide insight on the time and effort required to start the next phase of the study | |
| Travel time | Determine the amount of travel time to and from each visit | ||
| Administration of Informed Consent | Record the start and stop time of the administration of the informed consent | ||
| Administration of Baseline Assessments | Record the start and stop time of the baseline assessments | ||
| Adverse events | Evaluation of minimal risk | Follow established Federal guidelines for reporting | |
| Participants’ experience | Use statistical methods, such as ratios and proportions, and qualitative methods, specifically focus groups, to evaluate aspects of participants’ experience, adherence, and satisfaction | Quantitative findings can assist with power calculations and effect size for future studies | |
| Participant adherence | |||
| Participants’ satisfaction | |||
| Overall feasibility | Summarize quantitative and qualitative feasibility. | Use overall findings to inform Phase II and Phase III studies | |
| Effect size | Calculated based on ≥ 0.5 standard deviations | ||
| Qualitative content analysis | Directed content analysis will be used to ascertain codes about feasibility. Program modifications will also be evaluated for feasibility. |
Assessments for OVERATURE II.
| Measures | Pre-Assessment (Baseline) | Post-Assessment |
|---|---|---|
| 36-item Medical Outcomes scale SF-36 [ | ||
| Subjective Wellbeing Scale17 (Modified) [ | ||
| Physical Activity Scale for the Elderly (PASE) [ | ||
| Charlson Comorbidity Index (CCI) [ | ||
| Body Mass Index (BMI) [ | ||
| Blood Pressure | ||
| Short-Physical Performance Battery (SPPB) [ | ||
| Handgrip Strength [ |